Found 142 clinical trials
-
Accepting Seniors
-
Accepting adults
-
For females only
-
Family Medicine
-
Currently Recruiting
Platinum-Resistant Ovarian Cancer
A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208) Women with platinum resistant ovarian cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.
- 60 views
- 18 Feb, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
For females only
-
Currently Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- 1940 views
- 23 Nov, 2020
- 106 locations
-
Accepting pediatric ages
-
For females only
-
Currently Recruiting
Ovarian, Fallopian Tube or Peritoneal Cancer
Ovarian, Fallopian Tube or Peritoneal Cancer
- 616 views
- 08 Nov, 2020
- 1 location
-
Accepting pediatric ages
-
For females only
-
Currently Recruiting
GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
GOG 0225: Can Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
- 524 views
- 08 Nov, 2020
- 1 location
-
Accepting Seniors
-
Accepting adults
-
For females only
-
Endocrinology
-
Currently Recruiting
Ovarian Cancer (OVATION 2)
People with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer are asked to participate in a research study being conducted by Northwell Health.
- 37 views
- 18 Feb, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
For females only
-
Family Medicine
-
Currently Recruiting
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- 856 views
- 23 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
For females only
-
Currently Recruiting
Advanced Ovarian Cancer
Advanced Ovarian Cancer
- 116 views
- 08 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting adults
-
For females only
-
Currently Recruiting
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® with DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- 644 views
- 08 Nov, 2020
- 5 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
1000s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab Followed by Maintenance Durvalumab Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
- 84 views
- 17 Feb, 2021
- 282 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Family Medicine
-
Currently Recruiting
Study Of Intraperitoneal EGEN-001 Administered In Combination With Pegylated Liposomal-Doxorubicin In Patients With Recurrent Or Persistent Epithelial Ovarian Fallopian Tube Or Peritoneal Cancer
ovarian, fallopian tube or primary peritoneal cancer. - The tolerability of the combination at the MTD of EGEN-001 assessed in combination with PLD. - The
- 226 views
- 08 Nov, 2020
- 1 location